The US has approved Hemgenix - a one-time intravenous treatment for hemophilia B, a disorder in which people do not produce a protein needed to create blood clots and control bleeding.
Cell and gene therapies are offering patients potentially curative treatments for a growing scope of diseases. Insurance companies are trying to figure out how to pay for them. Industry consultants speaking at the HLTH conference offered some strategies they see payers taking to these new therapies.
In December 2021, China’s National Healthcare Security Administration (NHSA) published the 2021 National Reimbursement Drug List (2021 NRDL), implementing greater pricing discounts than those seen in 2020.
China’s National Healthcare Security Administration published the 2021 National Reimbursement Drug List, implementing greater pricing discounts than those seen in 2020. Out of 117 drugs negotiated, 74 were successfully added to the 2021 NRDL, including 67 with exclusivity.